Aller au contenu
MediHelp
MediHelp Référence médicamenteuse

Interactions médicamenteuses

Efgartigimod alfa + Nivolumab

Gravité: Modérée

Efgartigimod alfa and Nivolumab: moderate interaction.

Dernière mise à jour

Réservé aux professionnels de santé — à titre de référence uniquement. Cette page est un bref résumé, pas un avis médical, et ne remplace ni la notice officielle ni le jugement clinique. Vérifiez toujours avant de prescrire ou de délivrer.

Le contenu clinique de cette page n'est disponible qu'en anglais.

Résumé

Efgartigimod blocks the neonatal Fc receptor, which normally protects IgG antibodies from degradation. Nivolumab is an IgG4 antibody, so its clearance could increase and exposure fall, potentially weakening antitumor effect. The clinical significance is uncertain.

Ce que signifie cette interaction, en termes simples

Efgartigimod alfa and Nivolumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Efgartigimod alfa belongs to Miscellaneous; Nivolumab belongs to Oncology.

Niveau de preuve: Low

Pourquoi elle survient

Efgartigimod blocks FcRn-mediated IgG recycling, which may accelerate catabolism of IgG-based nivolumab.

Conduite à tenir

Avoid combining where possible, or monitor tumor response closely if efgartigimod is necessary. Consider timing nivolumab doses away from periods of maximal FcRn blockade only with specialist input.

Questions à poser à votre pharmacien

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Réservé aux membres Pro+

Débloquer la page complète

Créez un compte et lancez un essai Pro+ pour débloquer les conseils complets de prise en charge pour Efgartigimod alfa et Nivolumab, les notes complémentaires, le détail des données probantes et le vérificateur d'interactions pour une ordonnance complète.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription
Créer un compte gratuit Se connecter

Essayez Pro+ gratuitement pendant 7 jours sur le web. Sans carte.

Questions fréquentes

Can I take Efgartigimod alfa with Nivolumab?

MediHelp rates the interaction as moderate. Efgartigimod alfa and Nivolumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Efgartigimod blocks the neonatal Fc receptor, which normally protects IgG antibodies from degradation. Nivolumab is an IgG4 antibody, so its clearance could increase and exposure fall, potentially weakening antitumor effect. The clinical significance is uncertain.

How serious is the interaction between Efgartigimod alfa and Nivolumab?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid combining where possible, or monitor tumor response closely if efgartigimod is necessary. Consider timing nivolumab doses away from periods of maximal FcRn blockade only with specialist input.

What other medicines interact with Nivolumab?

MediHelp also lists interactions of Nivolumab with, for example, Thalidomide, Dexamethasone-tobramycin, Dexamethasone. The full list is on the Nivolumab page.

Monographies complètes, posologies et vérificateur d'interactions dans l'application MediHelp

Ouvrez le référentiel complet, vérifiez les interactions entre plusieurs médicaments et utilisez les outils de posologie dans l'application MediHelp.

Télécharger surApp Store Disponible surGoogle Play

Parcourir de A à Z · Interactions médicamenteuses

Télécharger l'app Se connecter